Skip to main content

Select Drug Profiles

Conference Correspondent, ASH 2016 - Multiple Myeloma
Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Sustained Overall Survival in Patients with Smoldering Myeloma Receiving Lenalidomide-Based Therapy
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Read More
Page 101 of 244
Results 1001 - 1010 of 2434